CTRI/2010/091/000496已完成2 期
A Randomized, Multicenter, Open Label, Comparative Study to Evaluate the Immunogenicity and Reactogenicity of a New Fully Liquid Hexavalent DTwP-Hepb-Hib-IPV Vaccine (EasysixTM, Panacea Biotec Ltd.) with Pentavalent DTwP-Hepb/Hib Vaccine (Tritanrix-HBTM Reconstituted with HiberixTM, GSK) Co Administered with Imovax Polio® (Salk Based Inactivated Polio Vaccine; sanofi pasteur India Pvt. Ltd.) in Healthy Infants. - EasySix Phase III
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 666
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Newborn infants (subject age upto 27 days) whose parents/LAR are willing to give written informed consent prior to the study entry.
- •2.Born at full term pregnancy (more than equal to 37 weeks) with a birth weight more than equal to 2.5 Kg.
- •3.Infants with good health as determined by Medical history, Physical examination and Clinical judgment of the investigator
- •4.Infants who are not seroprotected against diphtheria, tetanus, pertussis, Hepatitis B, H. influenzae type b or Polio by virtue of previous immunization and/or antigen exposure.
- •5.Judged to be able to attend all scheduled study visits and to comply with trial procedures.
排除标准
- •1.Parents or legal guardians are unwilling or unable to give written informed consent for infant's participation in the study.
- •2.Newborns requiring hospitalization for more than 1 day.
- •3.Known history of HBsAg positivity in mother.
- •4.History of immunization with zero dose of OPV, or Hepatitis B.
- •5.Subject is less than 6 weeks or more than 7 weeks of age.
- •6.Infants having history of previous immunization or infection with one of the vaccine constituents.
- •7.Presence of evolving or changing neurological disorder or Infants with history of seizures before receiving the vaccine. Initiation or continuation of pertussis vaccination should be deferred until an evolving neurological disorder can be excluded.
- •8.History of household contact and/or intimate exposure to an individual with suspected poliomyelitis.
- •9.Fever > 38°C in past 3 days
- •10.Any evidence of acute illness or infection within past 7 days.
- •11.Planned or elective surgery during the course of the study.
- •12.Infants with a known or suspected impairment of the immune function, or those receiving immunosuppressive therapy, or received immunosuppressive therapy within 1 month prior to study entry (including systemic or inhaled corticosteroids) or those who have received a parenteral immunoglobulin preparation
- •13.Infants who have received any blood products, cytotoxic agents or radiotherapy.
- •14.Infants with history of anaphylaxis, or any serious vaccine reaction, or allergy to any vaccine component.
- •15.Have any clinically significant chronic disease (for example, cardiac, pulmonary, renal, gastrointestinal, hepatic, endocrine, cancer, skin or psychiatric disease or disorder or autoimmune disease under treatment) such that it would endanger the volunteer's well being or which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
- •16.Any evidence of thrombocytopenia or a bleeding disorder.
- •17.Infants who have participated in another trial of an investigational agent within 30 days of enrolment.
研究者
相似试验
Unknown
3 期
A Multicenter, Open Label, Comparative Study to Evaluate a Fully Liquid Pentavalent DTwP-HepB-Hib Vaccine (EasyfiveTM, Panacea Biotec Ltd.) with Pentavalent DTwP-HepB/Hib Vaccine (Tritanrix-HBTM Reconstituted With HiberixTM, GSK) in Healthy Infants.CTRI/2012/02/002430Panacea Biotec Ltd600
Unknown
2 期
A Multicenter, Open Label, Comparative Study to Evaluate the effectiveness of a Fully Liquid Pentavalent DTwP-HepB-Hib Vaccine (MyFiveTM, Panacea Biotec Ltd.) with Pentavalent DTwP-HepB/Hib Vaccine (Tritanrix-HBTM Reconstituted(Mixed) With HiberixTM, GSK) in Healthy Infants.CTRI/2011/12/002218PANACEA BIOTEC LIMITED600
已完成
3 期
A study of IN-SUPR-002 in Comparison With Fixed Dose Combination (FDC) of Fenofibrate and Rosuvastatin in Patients with Mixed DyslipidemiaCTRI/2014/02/004417Intas Pharmaceuticals Ltd240
已完成
2 期
A multicenter, open label, comparative study to evaluate the immunogenicity and reactogenicity of a new fully liquid pentavalent DTwP-Hib-IPV vaccine (EasyfourPolTM, Panacea Biotec Ltd.)in Healthy Infants.CTRI/2010/091/000498PANACEA BIOTEC LIMITED622
招募中
3 期
Efficacy and safety study to assess between three drugs (Inhaler) in patients with Chronic Obstructive Pulmonary DiseaseCTRI/2023/01/048668upin Limited